Jun 19, 2017 Microsaic Systems plc (AIM: MSYS), the developer of chip-based mass spectrometry (“MS”) instruments designed to improve the efficiency of pharmaceutical R&D, announces the following unaudited trading update as it approaches the end of the six month period to 30 June 2017. The Company advised the market on 13 December 2016 that it... Read more
Scientists facing highly complex characterization challenges can now gain a deeper understanding of their samples with new enhancements to the industry-leading Thermo Scientific Orbitrap Fusion Lumos Tribrid mass spectrometer that extend its power, performance and versatility. “When we launched the Orbitrap Fusion Lumos Tribrid mass spectrometer at ASMS two years ago, we redefined protein and... Read more
Basel, 05 June 2017 Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Second positive phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa... Read more
Basel, 05 June 2017 Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Second positive phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa... Read more
2017 2017/06/01 Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan Kusatsu/Shiga, Japan — Jun 1, 2017 — Takara Bio Inc. (Takara Bio) announced that the Clinical Trial Notification was submitted to PMDA (Pharmaceuticals and Medical Devices Agency; Japanese regulatory agency)... Read more
2017 2017/05/29 First patient enrolled into Oncolytic Virus HF10 phase II clinical trial in Japan Kusatsu/Shiga, Japan — May 29, 2017 — Takara Bio Inc. (Takara Bio), today announced that the first patient with melanoma has been enrolled into Oncolytic Virus HF10(TBI-1401) phase II clinical trial in Japan on May 26, 2017. In this clinical study,... Read more
Download PDF Read more
KARLSRUHE, Germany, May 22, 2017 /PRNewswire/ — Today Bruker announces the launch of its new S8 TIGER™ Series 2, the next-generation Wavelength Dispersive X-Ray Fluorescence (WDXRF) spectrometer. The S8 TIGER Series 2 is the most versatile WDXRF tool available for advanced quantitative elemental analysis in industrial and academic materials research, as well as in industrial quality... Read more
Basel, 18 May 2017 Roche presents the first Phase I efficacy and safety data on CEA-TCB (CEA CD3 TCB), a novel T-cell bispecific antibody targeting solid tumours Encouraging clinical activity in metastatic colorectal cancer after failure of at least two prior chemotherapy regimens to be presented at the ASCO Annual Meeting Roche (SIX: RO, ROG;... Read more